These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17573123)

  • 1. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.
    Amaral MD; Kunzelmann K
    Trends Pharmacol Sci; 2007 Jul; 28(7):334-41. PubMed ID: 17573123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis.
    Marcet B; Boeynaems JM
    Pharmacol Ther; 2006 Dec; 112(3):719-32. PubMed ID: 16828872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?
    Witko-Sarsat V; Sermet-Gaudelus I; Lenoir G; Descamps-Latscha B
    Mediators Inflamm; 1999; 8(1):7-11. PubMed ID: 10704083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of the CF defect by curcumin: hypes and disappointments.
    Mall M; Kunzelmann K
    Bioessays; 2005 Jan; 27(1):9-13. PubMed ID: 15612029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for cystic fibrosis.
    Wilschanski M; Kerem E
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for cystic fibrosis lung disease.
    Grasemann H; Ratjen F
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):653-9. PubMed ID: 20812885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New concepts of pathophysiology and therapy in cystic fibrosis].
    Hirche TO; Loitsch S; Smaczny C; Wagner TO
    Pneumologie; 2005 Nov; 59(11):811-8. PubMed ID: 16385442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.
    Ashlock MA; Olson ER
    Annu Rev Med; 2011; 62():107-25. PubMed ID: 21226613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis-associated liver disease.
    Herrmann U; Dockter G; Lammert F
    Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):585-92. PubMed ID: 20955961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of the CFTR gene in Slovak cystic fibrosis patients by DHPLC and subsequent sequencing: identification of four novel mutations.
    Kolesár P; Minárik G; Baldovic M; Ficek A; Kovács L; Kádasi L
    Gen Physiol Biophys; 2008 Dec; 27(4):299-305. PubMed ID: 19202204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bringing new treatments to the bedside in cystic fibrosis.
    Brennan AL; Geddes DM
    Pediatr Pulmonol; 2004 Feb; 37(2):87-98. PubMed ID: 14730652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis: therapies targeting specific gene defects.
    Thursfield RM; Davies JC
    Paediatr Respir Rev; 2012 Dec; 13(4):215-9. PubMed ID: 23069118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild processing defect of porcine DeltaF508-CFTR suggests that DeltaF508 pigs may not develop cystic fibrosis disease.
    Liu Y; Wang Y; Jiang Y; Zhu N; Liang H; Xu L; Feng X; Yang H; Ma T
    Biochem Biophys Res Commun; 2008 Aug; 373(1):113-8. PubMed ID: 18555011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations.
    Alibakhshi R; Kianishirazi R; Cassiman JJ; Zamani M; Cuppens H
    J Cyst Fibros; 2008 Mar; 7(2):102-9. PubMed ID: 17662673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel mutation of CFTR gene in a Korean patient with cystic fibrosis.
    Ko JM; Kim GH; Kim KM; Hong SJ; Yoo HW
    J Korean Med Sci; 2008 Oct; 23(5):912-5. PubMed ID: 18955805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.